HC Wainwright & Co. Reiterates Buy on Acasti Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Acasti Pharma (NASDAQ:ACST) and maintained a price target of $12, indicating confidence in the company's future performance.
September 26, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Acasti Pharma and maintained a $12 price target, suggesting a positive outlook for the company's stock.
The reiteration of a Buy rating and maintenance of a $12 price target by HC Wainwright & Co. suggests confidence in Acasti Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100